SCHEMBL8237371

SCHEMBL8237371

COC(=O)/C=C/c1ccc(N)c([N+](=O)[O-])c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.52
APP P05067 1/20 0.52
PTPN1 P18031 1/20 0.50
EPHX2 P34913 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
TYR P14679 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
MAPT P10636 7/20 0.48
ALDH1A1 P00352 5/20 0.48
GAA P10253 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 2/20 0.48
JAK2 O60674 1/20 0.48
P2RY6 Q15077 1/20 0.47
HPGD P15428 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18046810 1.00 TTR (0.52) TTRAPPPTPN1EPHX2CA12
SCHEMBL6168986 0.84 ALDH1A1 (0.57) TTRAPPPTPN1EPHX2CA12
SCHEMBL6168977 0.84 ALDH1A1 (0.57) TTRAPPPTPN1EPHX2CA12
SCHEMBL29913976 0.84 APP (0.66) TTRAPPPTPN1EPHX2CA12
SCHEMBL832781 0.83 MAPT (0.61) TTRAPPPTPN1EPHX2CA12
SCHEMBL358100 0.83 TUBB4A (0.63) TTRAPPEPHX2MAPTALDH1A1
SCHEMBL358099 0.83 TUBB4A (0.63) TTRAPPEPHX2MAPTALDH1A1
SCHEMBL832780 0.83 MAPT (0.61) TTRAPPPTPN1EPHX2CA12
SCHEMBL2842776 0.83 TTR (0.52) TTRAPPPTPN1EPHX2CA12
SCHEMBL29844141 0.83 TTR (0.52) TTRAPPPTPN1EPHX2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO HEALTH, INC. (US) 2024-03-05 US disclosed
US-11407717-B2 Benzimidazole derivatives and use thereof as IDH1 inhibitors KPC PHARMACEUTICALS, INC. (CN) 2022-08-09 US disclosed
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2022-03-10 US disclosed
EP-3932914-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, Inc. (US) 2022-01-05 EP disclosed
US-20210206728-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS KPC PHARMACEUTICALS, INC. (CN) 2021-07-08 US disclosed
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-04-27 US disclosed
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2020-10-22 US disclosed
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-12-17 US disclosed
US-20190241506-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS VALO HEALTH, INC. 2019-08-08 US disclosed
US-10266487-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 US disclosed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 US disclosed
US-9745253-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors FORMA THERAPEUTICS, INC. (US) 2017-08-29 US disclosed
WO-2016149099-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-09-22 WO disclosed
WO-2016149099-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-09-22 WO disclosed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 US disclosed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 US disclosed
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS Valo Health, LLC 2016-09-15 US disclosed
CN-1964944-A Indole derivatives as antiviral agents ANGELETTI P IST RICHERCHE BIO (IT) 2007-05-16 CN disclosed
WO-2007030080-A1 HETEROCYCLIC COMPOUNDS S*BIO PTE LTD (SG) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407717-B2 Benzimidazole derivatives and use thereof as IDH1 inhibitors IDH1, IDH3A, IDH2 TTR 1122/4885APP 1367/4885PTPN1 2150/4885
US-20220073452-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-20200331847-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-10988441-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-20160264518-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-10508077-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-10266487-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-20190241506-A1 ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-11919839-B2 Alpha-cinnamide compounds and compositions as HDAC8 inhibitors HDAC8, HDAC7, HDAC1 TTR 4723/4885APP 3208/4885PTPN1 3180/4885
US-20210206728-A1 BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS IDH1, IDH3A, IDH2 TTR 1122/4885APP 1367/4885PTPN1 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.